Valuation : Tyra Biosciences, Inc.

Market Cap 1.56B 1.34B 1.25B 1.15B 2.16B 149B 2.17B 14.84B 5.8B 75.06B 5.85B 5.73B 248B P/E 2026 *
-9.7x
P/E 2027 * -8.81x
Enterprise Value 1.07B 917M 859M 786M 1.48B 102B 1.49B 10.17B 3.98B 51.44B 4.01B 3.93B 170B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.34%
1 week+1.71%
Current month-18.04%
1 month-15.87%
3 months-21.22%
6 months-21.56%
Current year-0.61%
1 week 25.18
Extreme 25.18
26.99
1 month 24.61
Extreme 24.61
33.26
Current year 24.61
Extreme 24.61
40.65
1 year 11.7
Extreme 11.7028
40.65
3 years 6.42
Extreme 6.42
40.65
5 years 4.93
Extreme 4.93
40.65
10 years 4.93
Extreme 4.93
40.65
Manager TitleAgeSince
Chief Operating Officer 51 2018-10-31
Chief Executive Officer 46 2018-10-31
Director of Finance/CFO 69 2022-12-31
Director TitleAgeSince
Chairman 58 2019-02-28
Director/Board Member 46 2018-08-01
Director/Board Member 40 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
5/28/26 Free

Director

13,160 0.0221%
5/28/26 Free

Director

13,160 0.0221%
5/28/26 Free

Director

13,160 0.0221%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%+1.71%+102.87%+84.79% 1.56B
+3.31%-3.70%+61.03%+103.64% 70.64B
-0.46%+0.11%+49.85%+92.29% 66.11B
-1.03%+0.46%+8.14%-5.28% 27.98B
-2.41%-2.95%-9.77%+455.82% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
+1.02%+6.43%+269.42%+420.34% 20.4B
-0.05%+0.88%+34.57%-17.49% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-1.50%+2.92%+43.50%+151.30% 13.69B
Average -0.30%+1.06%+63.61%+182.86% 28.95B
Weighted average by Cap. +0.30%+0.66%+56.68%+154.06%

Financials

2026 *2027 *
Net sales - -
Net income -178M -153M -143M -131M -246M -16.97B -247M -1.69B -661M -8.55B -667M -653M -28.31B -212M -182M -170M -156M -293M -20.22B -294M -2.01B -787M -10.19B -795M -778M -33.72B
Net Debt -491M -421M -394M -361M -680M -46.86B -682M -4.67B -1.83B -23.62B -1.84B -1.8B -78.16B -323M -277M -259M -238M -448M -30.84B -449M -3.07B -1.2B -15.54B -1.21B -1.19B -51.44B
Logo Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).
Employees
87
Date Price Change Volume
26-08-27 US$26.13 -0.34% 253,994
26-08-26 US$26.22 -1.76% 286,933
26-08-25 US$26.69 +2.30% 317,813
26-08-24 US$26.09 +0.15% 321,120
26-08-21 US$26.05 +1.40% 493,596
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
26.13USD
Average target price
50.82USD
Spread / Average Target
+94.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TYRA Stock